 Home > Biochemistry News > Biotechnology News > "Science" The Hope of Parkinson's Treatment

"Science" The Hope of Parkinson's Treatment

 Last Update: 2021-10-09
 Source: Internet
 Author: User

Tags

cheaper therapy events

human cell

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Pulse electrical stimulation drives cell-type specific neuromodulation

Researchers at Carnegie Mellon University have discovered a way to make deep brain stimulation (DBS) more precise, with longer-lasting therapeutic effects than currently available methods

Gittis is an associate professor of biological sciences at Mellon College of Science and a faculty member at the Neuroscience Institute

"By looking for an intervention with long-term effects, we hope to greatly reduce the stimulation time, thereby minimizing side effects and extending the battery life of the implant

In 2017, Gittis laid the foundation for this treatment.

Since then, she has been trying to find a treatment strategy that is easier to apply to patients with Parkinson's disease

Gittis said: "This is a big improvement over other existing therapies

In the new research protocol, the researchers targeted specific neuronal subgroups in the globus pallidus (a region of the basal ganglia of the brain) and used short pulses of electrical stimulation

"This concept is not new

The first author of the paper, Teresa Spix (Teresa Spix), said that although there are many powerful theories, scientists have not fully understood why DBS works

“We’re a bit like playing with a black box

"Many times, those of us who work in basic scientific research laboratories do not necessarily have a lot of contact with actual patients

Next, neurosurgeons from the Pittsburgh Allegheny Health Network (AHN) will use Gittis research to conduct human safety and tolerability studies

"Aryn Gittis continues to carry out amazing research, elucidating our understanding of the pathology of the basal ganglia in movement disorders

Donald Whiting, AHN's chief medical officer, is one of the most important experts in the use of brain pacemakers in the United States.
He said the new agreement may open the door to experimental treatments
.

Tomycz said, "This work will really help design the future technologies we use in our brains and will help us achieve better results for these patients
.
"

Science

DOI

10.
1126/science.
abi7852

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.